TGA / PMDA / NMPA · Asia-Pacific
solution — TGA / PMDA / NMPA regulatory status
solution regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 1520 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 0.05% Voclosporin Ophthalmic Solution (VOS) | Phase 3 | Aurinia Pharmaceuticals | NCT04147650 |
| 0.9% Sodium Chloride Solution, Glenzocimab | Phase 3 | PARItec | 2024-514352-32-00 |
| 000434 | Phase 3 | Ferring Pharmaceuticals | 2024-512177-27-01 |
| 042011 | Phase 3 | George Institute for | 2024-512676-36-00 |
| 071102 | Phase 3 | Baxalta Innovations | 2023-509769-18-00 |
| 100-006 | Phase 3 | Cardiol Therapeutics | 2024-517688-21-00 |
| 1001 | Phase 3 | Biotest Farmaceutica Ltda | 2024-513002-60-00 |
| 105MS306 | Phase 3 | Biogen | 2023-505624-56-00 |
| 111-302 | Phase 3 | BioMarin Pharmaceutical Australia | 2023-508864-31-00 |
| 111-303 | Phase 3 | BioMarin Pharmaceutical Australia | 2024-513129-22-00 |
| 111-308 | Phase 3 | BioMarin Pharmaceutical Australia | 2024-517238-16-00 |
| 1438-0011 | Phase 3 | Boehringer Ingelheim | 2025-523869-22-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12403090 | Oral film compositions and dosage forms having precise active dissolution profiles | US |
| 12290597 | Oral film compositions and dosage forms having precise active dissolution profiles | US |
| 2025051711 | TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE | WO |
| 12023410 | Micro/nanobubble solutions for tissue preservation and generation thereof | US |
| 11992555 | Solid solution compositions and use in chronic inflammation | US |
| 2024094673 | RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH | WO |
| 11918654 | Solid solution compositions and use in severe pain | US |
| 11896417 | Time-varying kinetic modeling of high temporal-resolution dynamic pet data for multiparametric imaging | US |
| 11873350 | Dissolution of oxidized cellulose | US |
| 11872244 | Thixotropic oxidized cellulose solutions and medical applications thereof | US |
| 11844773 | Solid solution compositions and use in chronic inflammation | US |
| 11752223 | Method for producing Ac-225 solution and method for producing medicine using Ac-225 solution | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of solution?
solution currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get solution regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to solution?
This spoke lists 1520 published programs associated with solution in our pipeline index.